Putative role of ischemic postconditioning in a rat model of limb ischemia and reperfusion: involvement of hypoxia-inducible factor-1α expression

Por Wang, T., Zhou, Y.T., Chen, X.N., Zhu, A.X.
Publicado em 2014

Cloning and characterization of p97MAPK, a novel human homolog of rat ERK-3.

Por Zhu, A X, Zhao, Y, Moller, D E, Flier, J S
Publicado em 1994

Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells

Por Feng, M., Jin, J. Q., Xia, L., Xiao, T., Mei, S., Wang, X., Huang, X., Chen, J., Liu, M., Chen, C., Rafi, S., Zhu, A. X., Feng, Y.-X., Zhu, D.
Publicado no Sci Adv (2019)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

Por Michaelson, M D, Zhu, A X, Ryan, D P, McDermott, D F, Shapiro, G I, Tye, L, Chen, I, Stephenson, P, Patyna, S, Ruiz-Garcia, A, Schwarzberg, A B
Publicado em 2013

Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer

Por Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Earle, C. C., Kulke, M. H., Meyerhardt, J. A., Blaszkowsky, L. S., Zhu, A. X., Fidias, P., Vincitore, M. M., Mayer, R. J., Fuchs, C. S.
Publicado em 2009

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

Por Chan, J. A., Blaszkowsky, L. S., Enzinger, P. C., Ryan, D. P., Abrams, T. A., Zhu, A. X., Temel, J. S., Schrag, D., Bhargava, P., Meyerhardt, J. A., Wolpin, B. M., Fidias, P., Zheng, H., Florio, S., Regan, E., Fuchs, C. S.
Publicado em 2011

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

Por Blaszkowsky, L. S., Ryan, D. P., Szymonifka, J., Borger, D. R., Zhu, A. X., Clark, J. W., Kwak, E. L., Mamon, H. J., Allen, J. N., Vasudev, E., Shellito, P. C., Cusack, J. C., Berger, D. L., Hong, T. S.
Publicado no Ann Oncol (2014)

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Por Arnold, D, Fuchs, C S, Tabernero, J, Ohtsu, A, Zhu, A X, Garon, E B, Mackey, J R, Paz-Ares, L, Baron, A D, Okusaka, T, Yoshino, T, Yoon, H H, Das, M, Ferry, D, Zhang, Y, Lin, Y, Binder, P, Sashegyi, A, Chau, I
Publicado no Ann Oncol (2017)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

Por Hezel, A F, Noel, M S, Allen, J N, Abrams, T A, Yurgelun, M, Faris, J E, Goyal, L, Clark, J W, Blaszkowsky, L S, Murphy, J E, Zheng, H, Khorana, A A, Connolly, G C, Hyrien, O, Baran, A, Herr, M, Ng, K, Sheehan, S, Harris, D J, Regan, E, Borger, D R, Iafrate, A J, Fuchs, C, Ryan, D P, Zhu, A X
Publicado em 2014